Skip to content
Menu
Menu
Home
About Us
Senior Management Team
Board of Directors
Scientific Advisory Board
Pipeline
Technology
Overview
Neuro-Oncology
Neurology
Ophthalmology
Inflammation
News
Careers
Contact
Menu
Home
About Us
Senior Management Team
Board of Directors
Scientific Advisory Board
Pipeline
Technology
Overview
Neuro-Oncology
Neurology
Ophthalmology
Inflammation
News
Careers
Contact
Neurology
Neuroinflammation Pipeline Enables Patient Selection and PD
THE NEED
Chronic neuroinflammation
correlates with poor outcomes in a wide range of diseases (e.g. ALS, Alzheimer’s, Parkinson’s)
Neuroinflammation is
difficult to diagnose,
and current agents lack sufficient selectivity
OUR SOLUTION
Radiolabeled (
18
F) HD, selectively
images neuroinflammation
in multiple animal models
Enables patient selection followed by
treatment with anti-neuroinflammatory agent
coupled to HDT to
target reactive microglia
Observed to
cross BBB in 7 species
(young and aged)
STATUS:
Risk share via partnership for OP-801 while still maintaining companion diagnostic rights in neurology and cancer applications
Leveraging OP-801 to Achieve Human POC
OP-801: Powerful Proof of Concept for Selective Targeting
Imaged 60 minutes after OP-801 dose